FDA Expedited Pathways Explained: Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval, and RMAT
Updated on March 20,2026|Written by Patsnap Team
The FDA operates five distinct expedited programs for drugs and biologics addressing serious conditions with unmet medical need. These programs are frequently referenced in drug development news and press releases — but they are distinct in their criteria, benefits, and what they signal about a drug’s development stage and clinical promise. This guide explains each one clearly.
All designation activity data referenced is sourced from Patsnap Synapse, which tracks ERP designations in real time across FDA, NMPA, EMA, PMDA, and other major agencies.
Why Expedited Pathways Exist
Standard FDA drug review takes approximately 10 months after an NDA or BLA submission. For drugs targeting serious conditions with limited or no existing treatments, this timeline — combined with a typical 10–15-year development cycle — delays patient access to potentially life-saving therapies.
The FDA introduced and expanded its expedited programs between 1988 (Accelerated Approval, for HIV/AIDS drugs) and 2016 (RMAT) to address this. These programs do not lower the safety or efficacy bar for approval; they accelerate the development and review process while maintaining the same evidentiary standards.
For the FDA’s official overview, see FDA’s expedited programs page.
1. Fast Track Designation
What it is: A designation granted to drugs in early development that show potential to address unmet medical need for serious conditions. It is the most broadly applied of the five programs.
When it’s granted: Based on preclinical data or early Phase 1 results — earlier in development than any other expedited designation.
Benefits:
– More frequent meetings and communications with FDA throughout development
– Rolling NDA/BLA review — FDA begins reviewing completed sections of the application before the full submission, shortening review time after submission
– Eligibility for Priority Review upon submission if the drug meets criteria
What it signals: Early promise, but not necessarily that clinical data is yet available to demonstrate substantial improvement over existing therapies. It is a development tool, not a regulatory validation of efficacy.
February 2026 examples: TSRA-196 (gene editing for Alpha-1 Antitrypsin Deficiency), ART-6043 (POLQ inhibitor for BRCA-mutated breast cancer), Sonelokimab (IL-17A/F nanobody for pustulosis of palms and soles)
2. Breakthrough Therapy Designation (BTD)
What it is: The most substantive of the expedited designations. Granted when preliminary clinical evidence indicates a drug may offer substantial improvement over existing therapies on a clinically significant endpoint for a serious condition.
When it’s granted: Requires preliminary clinical data — typically Phase 1 or Phase 2 results demonstrating a meaningful effect size compared to available therapy.
Benefits:
– All Fast Track benefits
– Intensive guidance from senior FDA staff throughout development
– Organisational commitment involving cross-disciplinary FDA review teams
– Rolling review
– Priority Review upon submission
What it signals: Meaningful preliminary clinical efficacy — a drug with BTD has shown early clinical data that suggests it may be a step-change over current standard of care.
February 2026 examples: Rilzabrutinib (wAIHA, Sanofi), NGN-401 (Rett Syndrome, Neurogene), GFH-375 (KRAS G12D NSCLC, Genfleet), Calderasib (KRAS G12C NSCLC, MSD China)
China’s NMPA operates an equivalent programme called Breakthrough Therapy Designation (突破性治疗药物), introduced in 2020. Six of the 12 February 2026 BTDs came from the NMPA.
Tracking every Breakthrough Therapy designation as it happens — connected to patent data and clinical trial context? Monitor BTD activity on Patsnap Synapse →
3. Priority Review
What it is: A designation applied to the NDA or BLA submission itself (not to the drug in development), shortening FDA’s review clock from the standard 12 months to 6 months.
When it’s granted: At the time of NDA/BLA submission, when the drug addresses an unmet medical need for a serious condition. A drug may receive other designations (Fast Track, BTD) earlier in development and then receive Priority Review at submission.
Benefits:
– Shorter review timeline (6 months vs 12 months standard)
– Does not involve more guidance during development
What it signals: FDA agrees the drug offers potential improvement over existing therapy at the point of application. Many Priority Reviews are granted to drugs that already hold Fast Track or BTD status — Priority Review is the “finish line” benefit at submission.
February 2026 examples: Olezarsen Sodium (hypertriglyceridemia, Ionis), Pariglasgene brecaparvovec (Glycogen Storage Disease I, Ultragenyx), Marstacimab (Hemophilia A/B, Pfizer)
Patsnap Synapse tracks every approval and ERP designation across FDA, NMPA, EMA, and PMDA in real time — connected to patent, clinical trial, and competitive data. Explore regulatory intelligence →
4. Accelerated Approval
What it is: An approval pathway that allows drugs to be approved based on a surrogate or intermediate clinical endpoint — one that is reasonably likely to predict clinical benefit — rather than requiring a direct measure of clinical outcomes such as survival.
When it applies: Serious conditions where the clinical endpoint would take too long to measure in trials (e.g., overall survival in cancer), but a reliable surrogate is available (e.g., tumor response rate, annualised height velocity, CD4 count).
Requirements: Post-market confirmatory trials verifying actual clinical benefit are required. If confirmatory trials fail, the FDA can withdraw Accelerated Approval — which has been done for several oncology drugs under recent FDA policy strengthening.
What it signals: The drug has demonstrated meaningful activity on a surrogate endpoint, with clinical benefit to be confirmed. Accelerated Approval is both a development tool and a mechanism for early patient access.
February 2026 examples:
– Navepegritide (Yuviwel) — approved based on annualized height velocity as surrogate endpoint for achondroplasia; confirmatory survival/functional data required
– Pegzilarginase — approved based on plasma arginine reduction as surrogate for hyperargininemia
For more on Navepegritide, see Navepegritide (Yuviwel): NPRC mechanism and clinical data.
5. RMAT (Regenerative Medicine Advanced Therapy)
What it is: A designation specific to cell therapies, gene therapies, and tissue-engineered products — created under the 21st Century Cures Act (2016). It provides the most intensive FDA support for regenerative medicine developers.
When it’s granted: For regenerative medicine therapies that show preliminary clinical evidence of addressing an unmet need in serious conditions.
Benefits:
– All Breakthrough Therapy benefits (intensive guidance, rolling review)
– Early interactions with FDA on surrogate endpoints and post-market studies
– Priority Review at submission
– Potential for accelerated approval based on surrogate/intermediate endpoints specific to regenerative medicine
What it signals: This is the highest-tier designation for cell and gene therapy products. Very few are granted — typically under 20 per year.
February 2026 example: KB-707 (IL-12/IL-2 cytokine therapy, Krystal Biotech) — for advanced NSCLC
BD teams and portfolio managers use Patsnap Synapse to assess asset value, identify licensing opportunities, and track competitor milestones. See how Synapse supports BD decisions →
How the Five Pathways Relate to Each Other
A single drug can hold multiple designations simultaneously:
Fast Track → obtained early (Phase 1/preclinical)
+ Breakthrough Therapy → obtained when Phase 2 data emerges
+ Priority Review → applied to the NDA/BLA at submission
+ Accelerated Approval → approval based on surrogate endpoint
RMAT replaces Breakthrough Therapy for regenerative medicine products but provides equivalent or greater benefits.
| Pathway | Granted | Based on | Primary benefit |
|---|---|---|---|
| Fast Track | During development | Preclinical / Phase 1 | More FDA meetings, rolling review |
| Breakthrough Therapy | During development | Preliminary clinical data | Intensive senior FDA guidance, rolling review |
| Priority Review | At NDA/BLA submission | NDA/BLA content | 6-month review clock |
| Accelerated Approval | At approval | Surrogate endpoint data | Earlier approval, confirmatory trials post-market |
| RMAT | During development | Preliminary clinical data (regenerative medicine) | BTD benefits + regenerative medicine-specific support |
NMPA Equivalent Programs (China)
China’s NMPA operates parallel expedited programs: Breakthrough Therapy (突破性治疗药物, 2020), Priority Review (优先审评审批, 2016), and Conditional Marketing Approval (附条件批准, 2017) — broadly equivalent to their FDA counterparts. In February 2026, 6 of 12 BTDs globally came from the NMPA. See the ERP overview for February 2026 for the full picture.
Patsnap Synapse tracks every ERP designation across FDA, NMPA, EMA, and PMDA — connected to patent estates, clinical trial timelines, and competitive landscapes for each designated drug. Explore regulatory intelligence on Synapse →
Monthly drug approvals, ERP designations, competitor pipeline shifts — Patsnap Synapse helps drug development and BD teams stay ahead of the curve. Request a demo →
Further Reading
- Expedited review pathways: 82 designations in February 2026
- Breakthrough Therapy designations — February 2026
- Navepegritide (Yuviwel) — Accelerated Approval for achondroplasia
- Rilzabrutinib — Breakthrough Therapy in wAIHA
- Global drug approvals roundup — February 2026
This post is for educational and informational purposes. For regulatory submissions, consult a qualified regulatory affairs professional.
